title: Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.
authors.affiliation: Department of Haematology, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore, grace.kam@sgh.com.sg.
authors.forename: Grace
authors.initials: G
authors.lastname: Kam
authors.forename: Richard
authors.initials: R
authors.lastname: Yiu
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Loh
authors.forename: Ai Leen
authors.initials: AL
authors.lastname: Ang
authors.forename: Ling Ling
authors.initials: LL
authors.lastname: Yueh
authors.forename: Yeow Tee
authors.initials: YT
authors.lastname: Goh
authors.forename: Gee Chuan
authors.initials: GC
authors.lastname: Wong
mesh_terms: D000293:Adolescent; D000328:Adult; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000453:epidemiology / Q000517:prevention & control; D060830:Consolidation Chemotherapy / Q000009:adverse effects / Q000379:methods; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; C486981:pegylated granulocyte colony-stimulating factor, human; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D000069585:Filgrastim